Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2018 Aug 1;8(7):e021704.
doi: 10.1136/bmjopen-2018-021704.

Prevalence of atrial fibrillation and cardiovascular risk factors in a 63-65 years old general population cohort: the Akershus Cardiac Examination (ACE) 1950 Study

Trygve Berge  1   2 , Magnus Nakrem Lyngbakken  2   3 , Håkon Ihle-Hansen  1   2 , Jon Brynildsen  2   3 , Mohammad Osman Pervez  2   3 , Erika Nerdrum Aagaard  2   3 , Thea Vigen  2   3 , Brede Kvisvik  2   3 , Ingrid Elisabeth Christophersen  1 , Kjetil Steine  2   3 , Torbjørn Omland  2   3 , Pål Smith  2   3 , Helge Røsjø  2   3 , Arnljot Tveit  1   2
Affiliations
Observational Study

Prevalence of atrial fibrillation and cardiovascular risk factors in a 63-65 years old general population cohort: the Akershus Cardiac Examination (ACE) 1950 Study

Trygve Berge et al. BMJ Open. .

Abstract

Objectives: To investigate the sex-specific prevalence of atrial fibrillation (AF), including subclinical AF found by screening in a general population aged 63-65 years. The prevalence of cardiovascular risk factors and their association with AF will also be investigated.

Design: Cross-sectional analysis of an observational, prospective, longitudinal, population-based cohort study.

Setting: General population in Akershus county, Norway.

Participants: Women and men born in 1950. We included 3706 of 5827 eligible individuals (63.6%); 48.8% were women.

Methods: All participants underwent extensive cardiovascular examinations, including 12-lead ECG. History of AF and other cardiovascular diseases were self-reported. Subsequent validation of all reported or detected AF diagnoses was performed.

Results: Mean age was 63.9±0.7 years. Prevalence of ECG-verified AF was 4.5% (women 2.4%, men 6.4%; p<0.001), including screen-detected AF in 0.3% (women 0.1%, men 0.6%; p<0.01). Hypertension was found in 62.0% (women 57.8%, men 66.0%; p<0.001). Overweight or obesity was found in 67.6% (women 59.8%, men 74.9%; p<0.001). By multivariate logistic regression, risk factors associated with AF were height (OR 1.67 per 10 cm; 95% CI 1.26 to 2.22; p<0.001), weight (OR 1.15 per 10 kg; 95% CI 1.01 to 1.30; p=0.03), hypertension (OR 2.49; 95% CI 1.61 to 3.86; p<0.001), heart failure (OR 3.51; 95% CI 1.71 to 7.24; p=0.001), reduced estimated glomerular filtration rate (OR 2.56; 95% CI 1.42 to 4.60; p<0.01) and at least one first-degree relative with AF (OR 2.32; 95% CI 1.63 to 3.31; p<0.001), whereas male sex was not significantly associated (OR 1.00; 95% CI 0.59 to 1.68; p=0.99).

Conclusion: In this cohort from the general population aged 63-65 years, we found a higher prevalence of known AF than previously reported below the age of 65 years. The additional yield of single time point screening for AF was low. Body size and comorbidity may explain most of the sex difference in AF prevalence at this age.

Trial registration number: NCT01555411; Results.

Keywords: atrial fibrillation; cardiac epidemiology; cardiovascular risk; obesity; prevalence; screening.

PubMed Disclaimer

Conflict of interest statement

Competing interests: TB has (outside this work) received honoraria from Boehringer-Ingelheim, Bayer and Pfizer/Bristol-Myers Squibb. TO has (outside this work) received honoraria or research support from Abbott, AstraZeneca, Bayer, Novartis, Roche, Singulex and Thermo Fisher. HR has (outside this work) received honoraria or research support from Novartis, CardiNor AS and SpinChip Diagnostics. TO and HR are partners in a patent filed by the University of Oslo regarding the use of secretoneurin as a biomarker in patients with cardiovascular disease and patients with critical illness.

Figures

Figure 1
Figure 1
Flow chart of Akershus Cardiac Examination (ACE) 1950 study population and atrial fibrillation (AF) prevalence.
See this image and copyright information in PMC

References

    1. Zoni-Berisso M, Lercari F, Carazza T, et al. . Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol 2014;6:213–20. 10.2147/CLEP.S47385 - DOI - PMC - PubMed
    1. Wolowacz SE, Samuel M, Brennan VK, et al. . The cost of illness of atrial fibrillation: a systematic review of the recent literature. Europace 2011;13:1375–85. 10.1093/europace/eur194 - DOI - PubMed
    1. Friberg L, Bergfeldt L. Atrial fibrillation prevalence revisited. J Intern Med 2013;274:461–8. 10.1111/joim.12114 - DOI - PubMed
    1. Kirchhof P, Benussi S, Kotecha D, et al. . ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;2016:2893–962. - PubMed
    1. Lowres N, Neubeck L, Redfern J, et al. . Screening to identify unknown atrial fibrillation. A systematic review. Thromb Haemost 2013;110:213–22. 10.1160/TH13-02-0165 - DOI - PubMed

Publication types

MeSH terms

Associated data